Senses Disorder TRIZ Cases

Decolorized Pandanus conoideus fruit extracts retain high pharmacological activity while eliminating skin discoloration risks.

Copper ion-doped carbon dots generate singlet oxygen under visible and near-infrared light for photodynamic therapy.

Segmentation and parameter changes in azabicyclic carboxamide structures improve functional activity while resolving safety profile limitations.

Humanized antibodies bind distinct beta-amyloid epitopes to inhibit monomer aggregation and dissolve preformed fibrils, reducing plaque load in ocular tissues.

A sustained-release d-MAPPS ocular implant delivers mesenchymal stem cell-derived exosomes and osmoprotectants to the eye.

Sterile filtration and ultrafiltration concentrate hyaluronic acid solutions while preserving molecular weight.

Anti-DEspR antibodies bind the dual endothelin/VEGF signal peptide receptor to block pathological angiogenesis.

Topical dobesilic acid ointment bypasses anterior barriers to reach the posterior eye segment.

Optimized variable domain sequences achieve picomolar specificity for PDGFRβ, resolving the trade-off between binding strength and isoform selectivity.

Novel heterocyclic sulfonamides act as selective AMPA receptor modulators to treat neurological disorders.

Pteridine derivatives modulate RORγ to treat autoimmune disorders while maintaining metabolic stability and therapeutic efficacy.

Antisense oligonucleotides target the c.2991+1655 A>G mutation in the CEP290 gene, preventing cryptic exon inclusion to treat Leber congenital amaurosis.

Topical IL-1Ra formulations treat blepharitis by restricting drug absorption locally, avoiding systemic side effects from steroids.

Flow cytometry with fluorescent antibodies isolates homogeneous human retinal progenitor cell populations for therapeutic use.

Pyrimidone derivatives inhibit GSK3β enzyme activity, resolving limited efficacy and specificity of existing inhibitors in treating neurodegenerative diseases.

Modular TALE-repeat units enable precise gene targeting by resolving specificity and efficiency trade-offs in higher eukaryotic cells.

A pharmaceutical composition combines a muscarinic receptor antagonist with a miotic agent to inhibit axial lengthening of the eye.

Peptides inhibit collagen synthesis to promote tissue regeneration, avoiding side effects from repeated intravitreal injections.

Substituted spirocyclic azaindole derivatives bind μ-opioid and ORL-1 receptors simultaneously.

Indole compounds inhibit fatty acid amide hydrolase to elevate endocannabinoid levels.

A pyrazolone derivative inhibits ocular angiogenesis to treat ophthalmologic diseases.

Selective CB2 agonists treat inflammation and pain without triggering psychoactive side effects from CB1 activation.

Controlled crystallization yields a stable RIPK1 inhibitor form that improves bioavailability while maintaining shelf-life.

GPR40 agonist compounds modulate insulin secretion to address beta cell dysfunction and insulin resistance in type 2 diabetes treatment.

Quinoline compounds inhibit alpha5beta1 integrin, blocking fibroblast activation and extracellular matrix synthesis to treat fibrotic disorders.

Receptor tyrosine kinase inhibitors treat neurodegenerative disease by promoting neuronal survival and regeneration instead of reducing intraocular pressure.

Crosslinked hyaluronic acid gel incorporates polyols and lidocaine to withstand heat sterilization, preserving viscoelasticity against thermal degradation.

A C5-binding antibody targets the MG4 domain to block complement activation.

Segmented differentiation protocols yield pure RPE cells, resolving mixed population bottlenecks for therapeutic use.

Fc-fused recombinant C1-INH extends serum half-life, reducing dosing frequency for hereditary angioedema treatment.

Tricyclic N-heteroaryl-carboxamide derivatives provide new TRPV1 receptor antagonists to address the unmet need for effective in vivo therapeutic agents.

Low oxygen culture conditions enhance human retinal progenitor cell proliferation and maintain multipotency.

Targeting PDE1B in microglia reduces pro-inflammatory cytokine signaling and enhances anti-inflammatory production.

Covalent antithrombin-heparin conjugates coat medical devices to prevent cognitive dysfunction from traveling thromboemboli during cardiopulmonary bypass.

Segmented porous silicon carriers in a permeable shell maintain stable drug concentrations without frequent dosing.

Activated protein C stabilizes the blood-retinal barrier, reducing CNV volume and preventing relapses common with anti-angiogenic therapies.

Site-directed mutagenesis of AAV capsids improves tissue tropism and overcomes low transduction limits.

Modular synthesis of N-(heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamides achieves potent TRPV1 antagonism while managing structural complexity.

Homologous recombination replaces the mouse gene with human NGF-beta to resolve low yield and poor bioactivity in mammalian cell cultures.

Fused heteroaromatic pyrrolidinone compounds inhibit spleen tyrosine kinase to improve specificity and efficacy for immune system disorders.

Engineered 2F11 antibodies target toxic alpha-synuclein conformations, overcoming the specificity barrier of traditional binders.

Acid-beta-glucocerebrosidase polypeptides degrade alpha-synuclein aggregates to mitigate cellular stress and delay synucleinopathy progression.

Formula I compounds modulate the complement cascade, treating disorders without increasing infection susceptibility.

Lyophilized epinephrine formulations eliminate preservative toxicity risks while maintaining stability through metal chelator extraction.

Soft acrylic intraocular lens materials incorporate a tack-reducing macromer additive to resolve handling difficulties during small-incision cataract surgery.

A truncated norrin protein variant extends biological half-life through protease-resistant mutations while maintaining Fzd4 receptor binding activity.